Skip to main content

Table 4 Enrollment and outcomes in studies using Zuspan or modified Zuspan regimens

From: An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

  Enrollment N Outcomes N (%)
Study Subjects Pre-eclampsia Eclampsia Affected patella reflex Respiratorydepression Oliguria Skipped dose Calcium gluconate Maternal death
All Due to MgSO4
ZUSPAN
Belfort 1 831 831 0    55    0 0
Coetzee 345 345 0   1    1 * 0 0
Deshmukh 2 18 12 6 0 1 0 0 1 0 0
Dommisse 3 11 0 11 0 0 0    0 0
Manorot 25 25 0 0 0 0 0 0 0 0
Mundle 147 147 0     134   0 0
SUBTOTALS 1377 1360 17 0 (0.0) 2 (0.15) 55 (4.0) 13 (0.9) 2 (0.15) 0 (0) 0 (0)
ZUSPAN MODIFIED
Aali 50 46 4 1    0 0 0 0
Chowdhury 150 0 150 0 0 0    5 0
Chissell 8 8 0 1 0 1 1   0 0
Dayicioglu 194 194 0      1 0 0
Phuapradit 44 44 0 0    0    
SUBTOTALS 446 292 154 2 (0.5) 0 (0) 1 (0.2) 1 (0.2) 1 (0.2) 5 (1.1) 0 (0)
TOTALS 1823 1652 171 2 (0.01) 2 (0.1) 56 (3.1) 14 (0.8) 3 (0.2) 5 (0.3) 0 (0)
  1. 1 Subjects received either Zuspan or Zuspan modified; 2 Eclamptics received Zuspan regimen; pre-eclamptics received modified Zuspan regimen; 3 Five eclamptics received Zuspan regimen and six received a modified Zuspan regimen; 4 6 stopped treatment due to woman’s request, side effects, oliguria or renal failure, or signs of toxicity and 7 due to provider error or provider preference (Personal communication); * Calcium gluconate administered after a magnesium sulfate dosing error caused respiratory depression.